Publication|Articles|March 16, 2026
Supplements and Featured Publications
- The Economic Value of Ozempic® (Semaglutide) Injection 0.5 mg, 1 mg, or 2 mg in Medicare Beneficiaries
The Economic Value of Ozempic® (Semaglutide) Injection 0.5 mg, 1 mg, or 2 mg in Medicare Beneficiaries
Listen
0:00 / 0:00
Advertisement
This clinical brief was created and sponsored by Novo Nordisk.
It is intended for payers, formulary committees, or other similar entities
with knowledge and expertise in the area of healthcare economic analysis,
carrying out their responsibilities for the selection of drugs for coverage
or reimbursement.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
Topical Delgocitinib Improves Chronic Hand Eczema Outcomes Across All Trial Timepoints
3
New Bill Would Cap Traditional Medicare Out-of-Pocket Costs at $5000
4
Community Oncology Must Adapt for CAR T, Bispecific Multiple Myeloma Care: Mohit Narang, MD
5